BRENDA - Enzyme Database show
show all sequences of 3.4.22.66

Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Kim, Y.; Lovell, S.; Tiew, K.C.; Mandadapu, S.R.; Alliston, K.R.; Battaile, K.P.; Groutas, W.C.; Chang, K.O.; J. Virol. 86, 11754-11762 (2012)

Data extracted from this reference:

Application
Application
Commentary
Organism
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Foot-and-mouth disease virus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Hepatovirus A
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Norwalk virus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
SARS coronavirus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Transmissible gastroenteritis virus
Crystallization (Commentary)
Crystallization
Organism
purified recombinant enzyme bound to inhibitor GC376, X-ray diffraction structure determination and analysis at 2.25 A resolution, molecular replacement
Transmissible gastroenteritis virus
purified recombinant enzyme free and bound to inhibitor (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid, X-ray diffraction structure determination and analysis at 1.50 and 1.65 A resolution, respectively, molecular replacement
Norwalk virus
Inhibitors
Inhibitors
Commentary
Organism
Structure
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Foot-and-mouth disease virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Hepatovirus A
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Norwalk virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
SARS coronavirus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Transmissible gastroenteritis virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Foot-and-mouth disease virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Hepatovirus A
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Norwalk virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
SARS coronavirus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Transmissible gastroenteritis virus
rupintrivir
-
Foot-and-mouth disease virus
rupintrivir
-
Hepatovirus A
rupintrivir
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
rupintrivir
-
Norwalk virus
rupintrivir
-
SARS coronavirus
rupintrivir
-
Transmissible gastroenteritis virus
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Foot-and-mouth disease virus
-
FMDV
-
Hepatovirus A
-
HAV
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
-
Noro virus strain MD145
-
SARS coronavirus
-
SARS-CoV
-
Transmissible gastroenteritis virus
P0C6V2
TGEV
-
Transmissible gastroenteritis virus Purdue
P0C6V2
TGEV
-
Norwalk virus
Q83883
-
-
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
Dabcyl-APAKQLLN-Edans + H2O
-
732410
Foot-and-mouth disease virus
Dabcyl-APAKQ + LLN-Edans
-
-
-
?
Dabcyl-GLRTQSFS-Edans + H2O
-
732410
Hepatovirus A
Dabcyl-GLRTQ + SFS-Edans
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
Transmissible gastroenteritis virus
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
SARS coronavirus
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
Transmissible gastroenteritis virus Purdue
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Edans-DFHLQGP-Dabcyl + H2O
-
732410
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
Edans-DFHLQ + GP-Dabcyl
-
-
-
?
Edans-DFHLQGP-Dabcyl + H2O
truncated substrate
732410
Norwalk virus
Edans-DFHLQ + GP-Dabcyl
-
-
-
?
Temperature Optimum [C]
Temperature Optimum [C]
Temperature Optimum Maximum [C]
Commentary
Organism
37
-
assay at
Foot-and-mouth disease virus
37
-
assay at
Hepatovirus A
37
-
assay at
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
37
-
assay at
Norwalk virus
37
-
assay at
SARS coronavirus
37
-
assay at
Transmissible gastroenteritis virus
pH Optimum
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
6
-
assay at
SARS coronavirus
6
-
assay at
Transmissible gastroenteritis virus
7
-
assay at
Hepatovirus A
8
-
assay at
Foot-and-mouth disease virus
8
-
assay at
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
8
-
assay at
Norwalk virus
IC50 Value
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
0.00049
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00055
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00061
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00064
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.0007
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
rupintrivir
0.00082
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00083
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
rupintrivir
0.00096
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00099
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00116
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00118
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00155
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00287
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00348
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00402
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00421
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
rupintrivir
0.00435
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00466
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.0426
-
pH 8.0, 37C, recombinant enzyme
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
rupintrivir
0.05
-
above, pH 6.0, 37C, recombinant enzyme
SARS coronavirus
rupintrivir
0.05
-
above, pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
rupintrivir
Application (protein specific)
Application
Commentary
Organism
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Foot-and-mouth disease virus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Hepatovirus A
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Norwalk virus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
SARS coronavirus
drug development
the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster
Transmissible gastroenteritis virus
Crystallization (Commentary) (protein specific)
Crystallization
Organism
purified recombinant enzyme bound to inhibitor GC376, X-ray diffraction structure determination and analysis at 2.25 A resolution, molecular replacement
Transmissible gastroenteritis virus
purified recombinant enzyme free and bound to inhibitor (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid, X-ray diffraction structure determination and analysis at 1.50 and 1.65 A resolution, respectively, molecular replacement
Norwalk virus
IC50 Value (protein specific)
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
0.00049
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00055
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00061
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00064
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.0007
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
rupintrivir
0.00082
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00083
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
rupintrivir
0.00096
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00099
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00116
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00118
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00155
-
pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00287
-
pH 8.0, 37C, recombinant enzyme
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00348
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.00402
-
pH 8.0, 37C, recombinant enzyme
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.00421
-
pH 8.0, 37C, recombinant enzyme
Foot-and-mouth disease virus
rupintrivir
0.00435
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.00466
-
pH 6.0, 37C, recombinant enzyme
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.0426
-
pH 8.0, 37C, recombinant enzyme
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
0.05
-
above, pH 8.0, 37C, recombinant enzyme
Hepatovirus A
rupintrivir
0.05
-
above, pH 6.0, 37C, recombinant enzyme
SARS coronavirus
rupintrivir
0.05
-
above, pH 6.0, 37C, recombinant enzyme
Transmissible gastroenteritis virus
rupintrivir
Inhibitors (protein specific)
Inhibitors
Commentary
Organism
Structure
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Foot-and-mouth disease virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Hepatovirus A
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Norwalk virus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
SARS coronavirus
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
-
Transmissible gastroenteritis virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Foot-and-mouth disease virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Hepatovirus A
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Norwalk virus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
SARS coronavirus
additional information
efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
Transmissible gastroenteritis virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Foot-and-mouth disease virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Hepatovirus A
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Norwalk virus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
SARS coronavirus
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
-
Transmissible gastroenteritis virus
rupintrivir
-
Foot-and-mouth disease virus
rupintrivir
-
Hepatovirus A
rupintrivir
-
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
rupintrivir
-
Norwalk virus
rupintrivir
-
SARS coronavirus
rupintrivir
-
Transmissible gastroenteritis virus
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
Dabcyl-APAKQLLN-Edans + H2O
-
732410
Foot-and-mouth disease virus
Dabcyl-APAKQ + LLN-Edans
-
-
-
?
Dabcyl-GLRTQSFS-Edans + H2O
-
732410
Hepatovirus A
Dabcyl-GLRTQ + SFS-Edans
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
Transmissible gastroenteritis virus
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
SARS coronavirus
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O
-
732410
Transmissible gastroenteritis virus Purdue
Dabcyl-KTSAVLQ + SGFRKME-EDANS
-
-
-
?
Edans-DFHLQGP-Dabcyl + H2O
-
732410
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
Edans-DFHLQ + GP-Dabcyl
-
-
-
?
Edans-DFHLQGP-Dabcyl + H2O
truncated substrate
732410
Norwalk virus
Edans-DFHLQ + GP-Dabcyl
-
-
-
?
Temperature Optimum [C] (protein specific)
Temperature Optimum [C]
Temperature Optimum Maximum [C]
Commentary
Organism
37
-
assay at
Foot-and-mouth disease virus
37
-
assay at
Hepatovirus A
37
-
assay at
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
37
-
assay at
Norwalk virus
37
-
assay at
SARS coronavirus
37
-
assay at
Transmissible gastroenteritis virus
pH Optimum (protein specific)
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
6
-
assay at
SARS coronavirus
6
-
assay at
Transmissible gastroenteritis virus
7
-
assay at
Hepatovirus A
8
-
assay at
Foot-and-mouth disease virus
8
-
assay at
Human calicivirus Hu/NLV/GII/MD145-12/1987/US
8
-
assay at
Norwalk virus
Other publictions for EC 3.4.22.66
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [C]
Temperature Range [C]
Temperature Stability [C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [C] (protein specific)
Temperature Range [C] (protein specific)
Temperature Stability [C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
732410
Kim
Broad-spectrum antivirals agai ...
Foot-and-mouth disease virus, Hepatovirus A, Human calicivirus Hu/NLV/GII/MD145-12/1987/US, Norwalk virus, SARS coronavirus, Transmissible gastroenteritis virus, Transmissible gastroenteritis virus Purdue
J. Virol.
86
11754-11762
2012
-
6
-
2
-
-
30
-
-
-
-
-
-
13
-
-
-
-
-
-
-
-
7
-
6
-
-
-
6
-
-
-
-
-
24
-
6
-
-
2
-
-
24
30
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7
-
6
-
-
-
6
-
-
-
-
-
-
-
-
-
718084
Oka
Comparative site-directed muta ...
feline calicivirus, Norwalk virus, Rabbit hemorrhagic disease virus, Sapporo virus
Microbiol. Immunol.
55
108-114
2011
-
-
-
-
8
-
-
-
-
-
-
-
-
11
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
8
8
-
-
-
693255
Lee
Structural basis of inhibition ...
Human coronavirus 229E
J. Biol. Chem.
284
7646-7655
2009
-
-
1
1
-
-
5
-
-
-
-
-
-
6
-
-
1
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
1
-
-
-
5
-
-
-
-
-
-
-
-
-
1
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
1
1
-
-
-
708950
Someya
Insights into the enzyme-subst ...
Chiba virus
J. Biochem.
146
509-521
2009
-
-
1
-
1
-
1
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
1
-
-
-
-
-
1
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
688730
Oka
Highly conserved configuration ...
feline calicivirus, Sapovirus
J. Virol.
81
6798-6806
2007
-
-
2
-
-
-
-
-
-
-
-
-
-
6
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
670097
Zeitler
X-ray crystallographic structu ...
Norwalk virus
J. Virol.
80
5050-5058
2006
1
1
1
1
1
-
2
-
-
-
-
-
-
4
-
-
1
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
1
1
1
-
1
1
-
-
2
-
-
-
-
-
-
-
-
-
1
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
670711
Asanaka
-
Replication and packaging of N ...
Norwalk virus
Proc. Natl. Acad. Sci. USA
19
10327-32
2006
-
1
1
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
688725
Sosnovtsev
Cleavage map and proteolytic p ...
Murine norovirus
J. Virol.
80
7816-7831
2006
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
670082
Nakamura
A norovirus protease structure ...
Chiba virus
J. Virol.
79
13685-13693
2005
-
1
1
1
-
-
-
-
-
-
-
-
-
3
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
670086
Belliot
Norovirus proteinase-polymeras ...
norovirus, norovirus MD145
J. Virol.
79
2393-2403
2005
-
1
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
671000
Someya
Characterization of the norovi ...
Chiba virus
Virus Res.
110
91-97
2005
1
-
1
-
1
-
12
-
-
-
1
-
-
4
-
-
1
-
-
-
-
-
1
-
1
1
-
-
1
1
-
-
-
-
-
1
-
1
-
-
1
-
-
12
-
-
-
-
1
-
-
-
-
1
-
-
-
-
1
-
1
1
-
-
1
1
-
-
-
-
-
-
-
-
670075
Kuyumcu-Martinez
Calicivirus 3C-like proteinase ...
Enterovirus C, feline calicivirus, norovirus, norovirus MD145-12
J. Virol.
78
8172-8182
2004
-
2
2
-
-
-
-
-
-
-
-
-
-
11
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
2
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
647402
Liu
Identification of further prot ...
Southampton virus
J. Gen. Virol.
80
291-296
1999
-
-
1
-
-
-
-
-
-
-
1
1
-
4
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
647401
Liu
Polyprotein processing in Sout ...
Southampton virus
J. Virol.
70
2605-2610
1996
-
-
1
-
-
-
-
-
-
-
-
-
-
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
647400
Lambden
A conserved sequence motif at ...
Southampton virus
Virus Genes
10
149-152
1995
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
647399
Lambden
Sequence and genome organizati ...
Southampton virus
Science
259
516-519
1993
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-